Clinical Trials Logo

Genital Neoplasms, Male clinical trials

View clinical trials related to Genital Neoplasms, Male.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03035357 Withdrawn - Prostate Cancer Clinical Trials

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Start date: March 1, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate) as part of their standard care. Biomarkers are found in the blood/tissue and may be related to your reaction to the study drug.

NCT ID: NCT02915172 Withdrawn - Advanced Cancer Clinical Trials

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Start date: December 2016
Phase: Phase 1
Study type: Interventional

There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenvatinib and Xeloda (capecitabine) that can be given to patients with advanced cancer. The goal of Phase 2 of this study is to learn if the dose of lenvatinib and capecitabine found in Phase 1 can help to control advanced cancer. The safety of this drug combination will be studied in both phases of the study.

NCT ID: NCT02812056 Withdrawn - Clinical trials for Malignant Neoplasms of Female Genital Organs

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of alisertib and TAK-228 that can be given to participants with advanced solid tumors that are associated with HPV. Researchers also want to learn if the study drug combination can help to control advanced solid tumors.